The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory, rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases. An argument for…
My children were playing in the car the other day and pulled open the glove box. Inside, they found a brown paper bag with my last name “KUMAR” in black Sharpie and a red sticker that read, “Do not lose. No replacements available.” It wasn’t long before the kids tore that bag apart to find…
Emerging evidence shows COVID-19 infection may have long-term consequences, such as arthritis onset and more.
In the early days of the COVID-19 pandemic, confusion and concern for immunosuppressed patients grew among rheumatologists and patients alike. Research has helped bridge the knowledge gap, and treatment options for COVID-19 have helped ease concerns.
SAN DIEGO—As part of a panel on systemic autoinflammatory diseases (SAIDs) at a Nov. 15 scientific session of ACR Convergence 2023, Sivia Lapidus, MD, shared context and insights on the therapeutic management of patients with these conditions. The Spectrum of SAIDs SAIDs encompass a broad swath of individually rare disorders driven by innate immune responses…
We are honored to announce that The Rheumatologist has received two Awards of Excellence from APEX 2023 for content published in calendar year 2022: an Award of Excellence in the category of Public Health Concerns—Health & Medical for the editorial supplement to the April issue, COVID-19: What We Know, and an Award of Excellence for…
NEW ORLEANS—The COVID-19 pandemic brought to light the interplay of the SARS-CoV-2 virus and the immune systems of infected patients. Acute autoimmune manifestations of COVID-19, such as multisystem inflammatory syndrome in children (MIS-C) and myocarditis, clearly exist. A session at the 2023 Pediatric Rheumatology Symposium, Autoantibodies in COVID-19 explored this topic in detail, including a…
Do you remember where you were when the COVID-19 Public Health Emergency (PHE) was declared on Jan. 31, 2020? While it may seem like yesterday, you would be forgiven for not recalling your exact location over three years ago during what felt like an incredible whirlwind for the healthcare industry. One possible location you may…
The public health emergency (PHE), in place since 2020, officially expired at midnight on May 11. The PHE declaration allowed significant flexibility in the healthcare system. The end of the PHE impacts several policies, including changes in Medicare and Medicaid policies. What do these changes mean for providers?
As COVID-19 case counts fade from the headlines and people return to their pre-pandemic routines, rheumatologists and rheumatology professionals may be wondering what “the end” of COVID-19 is going to look like for them. Much of that answer lies in the status of the federal emergencies that have been declared in response to COVID-19. These…